PubMed Health⌕ Search

PubMed · 9051339

Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data.

Abstract

The analysis of published survival curves can be the basis for incremental cost-effectiveness evaluations in which two treatments are compared with each other in terms of cost per life-year saved. The typical case is when a new treatment becomes available which is more effective and more expensive than the corresponding standard treatment. When effectiveness is expressed using the end-point of mortality, cost-effectiveness analysis can compare the (incremental) cost associated with the new treatment with the (incremental) clinical benefit measured in terms of number of life-years gained. The (incremental) cost-effectiveness ratio is therefore quantified as cost per life-year gained. This pharmacoeconomic methodology requires that the total patients years for the treatment and the control groups are estimated from their respective survival curves. We describe herein a survival-curve fitting method which carries our this estimation and a computer program implementing the entire procedure. Our method is based on a non-linear least-squares analysis in which the experimental points of the survival curve are fitted to the Gompertz function. The availability of a commercial program (PCNONLIN) is needed to carry out matrix handling calculations. Our procedure performs the estimation of the best-fit parameters from the survival curve data and then integrates the Gompertz survival function from zero-time to infinity. This integration yields the value of the area under the survival curve (AUC) which is an estimate of the number of patients years totalled in the population examined. If this AUC estimation is performed separately for the two survival curves of two treatments being compared, the difference between the two AUCs permits to determine the incremental number of patient years gained using the more effective of the two treatments as opposed to the other. The cost-effectiveness analysis can consequently be carried out. An example of application of this methodology is presented in detail.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Messori. 1997. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data.. https://doi.org/10.1016/s0169-2607(96)01788-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗

Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.

A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem cell rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

Antineoplastic Agents↗

Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.

Chronic myelogenous leukemia (CML) is rare in the pediatric population. Allogeneic stem cell transplant remains the only curative therapy; however, identifying a fully matched donor is not always possible. Imatinib mesylate has been shown to induce hematologic and cytogenetic response in adults and children with CML. We describe a child who achieved molecular remission with imatinib mesylate. BCR-ABL negative peripheral blood stem cells (PBSC) were successfully collected after mobilization with filgrastim.

Antineoplastic Agents↗